Billiontoone (NASDAQ:BLLN) Coverage Initiated at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Billiontoone (NASDAQ:BLLN) in a report released on Monday, MarketBeat reports. The brokerage set an “equal weight” rating and a $110.00 price target on the stock. Wells Fargo & Company‘s price target points to a potential downside of 4.28% from the company’s current price.

A number of other brokerages have also issued reports on BLLN. William Blair started coverage on shares of Billiontoone in a report on Monday. They issued an “outperform” rating for the company. Piper Sandler began coverage on shares of Billiontoone in a research note on Monday. They set an “overweight” rating and a $150.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Billiontoone in a research note on Monday. They issued a “hold” rating and a $117.00 price objective on the stock. Wall Street Zen upgraded Billiontoone to a “hold” rating in a report on Saturday, November 15th. Finally, Stifel Nicolaus assumed coverage on Billiontoone in a report on Monday. They set a “buy” rating and a $145.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and an average price target of $138.67.

Billiontoone Price Performance

Shares of BLLN opened at $114.92 on Monday. Billiontoone has a 12-month low of $88.00 and a 12-month high of $138.70.

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.